NPS down 3% after Reuters says Shire preparing for bids Shares of NPS Pharmaceuticals (NPSP) are down 3% to $33.57 after Reuters reported that Shire (SHPG) has hired Citi to prepare for takeover offers. Press reports have speculated that NPS is a buyout target of Shire.
Shire receives 'positive opinion' on Intuniv from CHMP Shire announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the approval of the once-daily, non-stimulant Intuniv, or guanfacine hydrochloride extended release, for the treatment of attention deficit/hyperactivity disorder in children and adolescents. The positive opinion is based on results from three Phase 3 pivotal studies investigating the short- and long-term safety and efficacy of Intuniv in children and adolescents. The European Commission will now consider the CHMP positive opinion in its decision of whether to grant marketing authorisation for Intuniv in Europe, said Shire.